US FDA approves Roivant-Priovant's skin disease drug
27/08/2026 20:26
US FDA approves Roivant-Priovant's skin disease drug Aug 27 (Reuters) - The U.S. Food and Drug Administration said on Thursday it approved a treatment from Roivant ROIV.O and partner Priovant Therapeutics for dermatomyositis, making it the first oral drug for the skin disease.
(Reporting by Christy Santhosh in Bengaluru; Editing by Vijay Kishore)
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple